Skip to main content



Favourable outcomes possible for autosomal recessive pseudohypoaldosteronism type 1

Increased cardiometabolic risk appears from childhood in CAH patients

Endocrinopathy risk highlighted among childhood brain tumour survivors

Collagenopathy may underlie some familial short stature cases without clear dysplasia

BMI link to earlier puberty onset in boys confirmed

Treatment advances translate to better congenital hyperinsulinism outcomes

GH therapy can bring Noonan syndrome children’s height within population norms

Global increase in childhood thyroid cancer implies overdiagnosis

02-12-2020 | Diabetes | News | Article

Real-world data support early insulin pump initiation in children

Starting children on an insulin pump within 6 months of type 1 diabetes diagnosis is associated with improved outcomes relative to delaying for 2 or 3 years, shows an analysis of data from the DPV registry.

09-11-2020 | Diabetes | News | Article

Children persist best with CGM if started concurrently with insulin pump

Children with type 1 diabetes make more consistent use of continuous glucose monitoring if they are given the device when they initiate insulin pump therapy, rather than several months later, show the CGM TIME Trial results.

28-09-2020 | Diabetes | News | Article

C-peptide a reliable guide to residual beta cells across ages, diabetes durations

Levels of circulating C-peptide in people with type 1 diabetes reflect the numbers of remaining beta cells across different ages at diagnosis and durations of disease, confirm UK researchers.

26-08-2020 | Diabetes | News | Article

​​​​​​​Closed-loop system improves glycemic control in children with type 1 diabetes

Children with type 1 diabetes who use the Tandem Control-IQ hybrid closed-loop insulin delivery system spend more time with their blood glucose levels in the target range than those using a sensor-augmented insulin pump, show findings from the iDCL trial.

25-08-2020 | Rheumatology | News | Article

Canakinumab monotherapy tapering feasible in systemic JIA

Canakinumab monotherapy tapering, either through dose reduction or dose interval prolongation, is feasible in children with systemic juvenile idiopathic arthritis who achieve clinical remission, study findings indicate.

26-05-2020 | Multiple sclerosis | Video

EAN 2020 | Teriflunomide shows benefits in children with relapsing forms of MS

Tanuja Chitnis tells us about the TERIKIDS study showing a numerical reduction in clinical relapse risk and a significant reduction in time to clinical relapse with teriflunomide  in paediatric patients with relapsing-remitting multiple sclerosis (5:29).

08-01-2020 | Diabetes | News | Article

Early puberty may raise type 2 diabetes risk in women

Earlier age at menarche is associated with an increased risk for type 2 diabetes and impaired glucose tolerance among women, and this association remains significant after adjustment for adiposity, suggest findings from a meta-analysis.

30-08-2019 | Rheumatology | News | Article

Observational data support long-term adalimumab use in polyarticular JIA

Adalimumab, used with or without concurrent methotrexate, appears to be well tolerated among children with polyarticular‐course juvenile idiopathic arthritis, 7-year data from the STRIVE registry show.

08-08-2019 | Diabetes | News | Article

Pros and cons of CGM described by parents of children with diabetes

Continuous glucose monitoring offers many benefits to the families of young children with type 1 diabetes but also a number of challenges that cannot always be overcome, show results of a qualitative analysis conducted in the USA.

09-05-2019 | Multiple sclerosis | Video

AAN 2019: Paediatric MS disability scoring system developed

Jonathan Santoro summarises their research evaluating disability distribution in paediatric-onset multiple sclerosis using a novel scoring model, and discusses the implications for the care of patients (4:31).

26-04-2019 | Diabetes | News | Article

School-based consultations boost diabetes clinic attendance in hard-to-reach teens

Meeting teenagers with diabetes at their schools to discuss concerns and reflect on self-management reduces the number who do not attend hospital clinics, say researchers.

04-04-2019 | Oncology | News | Article

LOXO-195 could be an option for tumors resistant to first-generation TRK inhibitors

Early findings point to the antitumor efficacy of the next-generation TRK inhibitor LOXO-195 in patients with NTRK fusion-positive cancers and NTRK resistance mutations acquired during treatment with first-generation agents.

Image Credits